I
118th CONGRESS
1st Session
H. R. 619
IN THE HOUSE OF REPRESENTATIVES
January 30, 2023
Mr. Tonko (for himself, Mr. Smith of New Jersey, and Ms. Waters) introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To extend the National Alzheimer’s Project.
Short title
This Act may be cited as the NAPA Reauthorization Act
.
Extension of project
Section 2 of the National Alzheimer’s Project Act (42 U.S.C. 11225) is amended—
in subsection (c)—
in paragraph (2), by striking and coordination of
and inserting on, and coordination of,
;
in paragraph (4)—
by redesignating subparagraphs (A) and (B) as subparagraphs (B) and (C), respectively; and
by inserting before subparagraph (B), as so redesignated, the following:
promotion of healthy aging and reduction of risk factors for Alzheimer’s;
;
in paragraph (5), by striking ; and
and inserting a semicolon;
by redesignating paragraph (6) as paragraph (7); and
by inserting after paragraph (5) the following:
provide information on, and promote the adoption of, healthy behaviors that may reduce the risk of cognitive decline and promote and protect cognitive health; and
;
in subsection (d)(2)—
by inserting , across public and private sectors,
after Nation’s progress
; and
by inserting , including consideration of public-private collaborations, as appropriate
before the period;
in subsection (e)—
in paragraph (2)—
in subparagraph (A), by adding at the end the following:
A designee of the Department of Justice.
A designee of the Federal Emergency Management Agency.
A designee of the Social Security Administration.
A designee of the Office of Management and Budget.
1 or more other designees of the Department of Health and Human Services, as determined by the Secretary of Health and Human Services.
; and
in subparagraph (B)—
in the matter preceding clause (i), by striking 12
and inserting 14
;
in clause (v)—
by striking 2 researchers
and inserting 3 researchers
; and
by striking ; and
and inserting , including at least one researcher with demonstrated experience in recruitment and retention of diverse cohorts of clinical trial participants;
;
in clause (vi), by striking the period and inserting ; and
; and
by adding at the end the following:
an individual with a diagnosis of Alzheimer’s disease.
;
in paragraph (5)—
in subparagraph (A)—
by striking an initial evaluation
and inserting annual evaluations
; and
by striking research, clinical
and inserting research, risk reduction, public health, clinical
;
in subparagraph (B), by striking initial
;
in subparagraph (C)—
in the matter preceding clause (i), by striking initial
; and
in clause (ii), by inserting and reduce disparities
before the semicolon; and
in subparagraph (D), by striking annually thereafter, an evaluation
and inserting annual evaluations
; and
in paragraph (6), by striking 2025
and inserting 2035
;
in subsection (g)(3)(A)(ii), by inserting and reduce disparities
before the semicolon; and
in subsection (h), by striking 2025
and inserting 2035
.
